Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 15Withdrawn 7Terminated 6Unknown 5Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasms 1

Interventions

Carboplatin 126Cisplatin 125Drug Therapy 103Bevacizumab 98Oxaliplatin 97Capecitabine 97Radiotherapy 94Gemcitabine 87Paclitaxel 85tislelizumab 84Cyclophosphamide 82pembrolizumab 77Specimen Handling 77toripalimab 69Injections 63Fluorouracil 62Magnetic Resonance Spectroscopy 61sintilimab 57anlotinib 53130-nm albumin-bound paclitaxel 51Surgical Procedures, Operative 50Docetaxel 49fludarabine 46Pemetrexed 45venetoclax 42Standard of Care 42Leucovorin 42Irinotecan 41lenvatinib 40Biopsy 39

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Interventional × Glutamine × Clear all
NCT07287592 2025-12-17

Glutamine for the Prophylaxis of Vincristine-induced Neuropathy in Children and Adolescents With Cancer.

Ain Shams University

Phase 3 Not yet recruiting
70 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡